Breadcrumb

Jeremy L. Davis, M.D.

Jeremy L. Davis, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Surgical Oncology Program

RESEARCH SUMMARY

Dr. Jeremy L. Davis is surgical oncologist whose research focuses on sporadic and inherited forms of stomach cancer, specifically those caused by germline mutations in the CDH1 gene, and the molecular underpinnings of gastric cancer development and metastasis.  Dr. Davis is board certified in both Complex General Surgical Oncology and General Surgery.

Areas of Expertise

1) gastric cancer 2) pancreatic cancer 3) hepatic metastasectomy 4) minimally-invasive and robotic surgery

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.

Patient Resources

From diagnosis to treatment and beyond, learn more about hereditary diffuse gastric cancer (HDGC) from this suite of patient resources.

Publications

Selected Key Publications

Early immune changes support signet ring cell dormancy in CDH1-driven hereditary diffuse gastric carcinogenesis.

Green BL, Gamble LA, Diggs LP, Nousome D, Patterson JC, Joughin BA, Gasmi B, Lux SC, Samaranayake SG, Miettinen M, Quezado M, Hernandez JM, Yaffe MB, Davis JL.
Mol Cancer Res. 2023. [ Journal Article ]

Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy

Gallanis AF, Gamble LA, Samaranayake SG, Lopez R, Rhodes A, Rajasimhan S, Fasaye GA, Juma O, Connolly M, Joyce S, Berger A, Heller T, Blakely AM, Hernandez JM, Davis JL. Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy
J Clin Oncol. 2023. [ Journal Article ]

Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study

Asif B, Sarvestani AL, Gamble LA, Samaranayake SG, Famiglietti AL, Fasaye GA, Quezado M, Miettinen M, Korman L, Koh C, Heller T, Davis JL.
Lancet Oncol.. 2023. [ Journal Article ]

Decision-making and regret in patients with germline CDH1 variants undergoing prophylactic total gastrectomy.

Gamble LA, Grant RRC, Samaranayake SG, Fasaye GA, Koh C, Korman L, Asif B, Heller T, Hernandez JM, Blakely AM, Davis JL.
J Med Genet.. 2022. [ Journal Article ]

Association Between Hereditary Lobular Breast Cancer Due to CDH1 Variants and Gastric Cancer Risk

Gamble LA, Rossi A, Fasaye GA, Kesserwan C, Hernandez JM, Blakely AM, Davis JL.
JAMA Surg. epub: 2022. [ Journal Article ]

Team

YVONNE
REFERRAL NURSE
Yvonne Mallory, BSN, R.N.
Kartrail Cutchember
Patient Care Coordinator
Kartrail Cutchember
Riema
CASE MANAGER
Riema Broesamle, MSN, R.N., CNEcl
Research Nurse
Jessica Turner, BSN, R.N.
Stacy
Physician Assistant
Stacy Joyce , PA-C
Charlotte Payne
Physician Assistant II
Charlotte Payne, P.A.-C
RESEARCH NURSE
Jamie Kirkpatrick, BSN, R.N.
Amber Famiglietti
Clinical Fellow
Amber Famiglietti, M.D.
Cassidy Bowden
POSTBACCALAUREATE FELLOW
Cassidy Bowden
Program Specialist
Joanna Lamot

Resources

Information for Healthcare Professionals

NIH Genetic and Rare Diseases Information Center

Patients are encouraged to visit the NIH Genetic and Rare Diseases Information Center (GARD) for more information about organizations supporting stomach cancer patients.